This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Marur S , Burtness B
Oropharyngeal squamous cell carcinoma treatment: current standards and future directions
Curr Opin Oncol. 2014 May;26(3) :252-8
PMID: 24626127 PMCID: PMC5813288 URL: https://www.ncbi.nlm.nih.gov/pubmed/24626127
AbstractPURPOSE OF REVIEW: To discuss the changing landscape and significant developments in the diagnosis and management of oropharyngeal squamous cell carcinoma. RECENT FINDINGS: High-risk human papilloma viruses (HPVs) have been recognized as important causative factors for oropharyngeal cancer. The diagnosis is established with type-specific and broad-spectrum in-situ hybridization probes and/or p16 immunohistochemistry assays on fresh frozen paraffin-embedded tissue blocks. HPV-associated tumors have superior response and outcomes compared with HPV-unrelated tumors. Retrospective studies have been able to stratify oropharyngeal squamous cell carcinoma based on HPV status, tumor stage, nodal stage, and smoking history into risk groups with differing risks of death or distant disease. Selected patients, nonsmokers with less advanced nodal stage, may be overtreated with current treatment paradigms, and deintensification of curative therapy is a current research focus for these patients. Smokers, patients with advanced nodal or tumor stage, and those with HPV-unrelated cancers have a less favorable prognosis and the search for novel targets is particularly important for these patients. SUMMARY: The present review will highlight the current standards and the future direction of novel therapies in both HPV-associated and HPV-unrelated cancers.
NotesMarur, Shanthi Burtness, Barbara eng U10 CA021115/CA/NCI NIH HHS/ U10 CA037403/CA/NCI NIH HHS/ U10 CA180802/CA/NCI NIH HHS/ UG1 CA189828/CA/NCI NIH HHS/ Research Support, Non-U.S. Gov't Review Curr Opin Oncol. 2014 May;26(3):252-8. doi: 10.1097/CCO.0000000000000072.